Table 1.
Current novel therapies in clinical trials. Information was obtained from clinicaltrials.gov.
| Intervention | Delivered Drug(s) | Pancreatic Cancer Stage | Phase | Trial Identifier |
|---|---|---|---|---|
| K-RAS-Targeting | siG12D-LODER with chemotherapy | Locally Advanced PC | Phase II | NCT01676259 |
| Decitabine 50 MG | KRAS-dependant refractory metastatic/recurrent Pancreatic Adenocarcinoma | Phase II | NCT05360264 | |
| Binimetinib Hydroxychloroquine |
KRAS Mutant Metastatic PC | Phase I | NCT04132505 | |
| Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA | Metastatic Pancreas Cancer with KrasG12D Mutation | Phase I | NCT03608631 | |
| mDC3/8-KRAS Vaccine | Pancreatic Ductal Adenocarcinoma | Phase I | NCT03592888 | |
| Vemurafenib Sorafenib |
Advanced KRAS G12D Mutated PC | Phase II | NCT05068752 | |
| NALRINOX combination (modified FOLFIRINOX) | Resectable Pancreatic Ductal Adenocarcinoma | Phase II | NCT04010552 | |
| ELI-002 2P | KRAS Mutated Pancreatic Ductal Adenocarcinoma | Phase I | NCT04853017 | |
| Binimetinib Palbociclib |
Operable KRAS-Positive Lung, Colorectal, or PC | Phase I | NCT04870034 | |
| Immunotherapies Combinations | Mitazalimab FOLFIRINOX |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase II | NCT04888312 |
| Cohort A: Nivolumab + Ipilimumab + Nab-paclitaxel + GEM Cohort B: Hydroxychloroquine + Ipilimumab + Nab-paclitaxel + GEM |
Untreated Metastatic Pancreatic Adenocarcinoma | Phase I | NCT04787991 | |
| Motixafortide, Cemiplimab, GEM, Nab-Paclitaxel | Pancreatic Adenocarcinoma | Phase II | NCT04543071 | |
| Nivolumab + Irreversible Electroporation | Advanced Pancreatic Adenocarcinoma | NCT03080974 | ||
| Avelumab and Pepinemab | Metastatic Pancreatic Adenocarcinoma | Phase I and II | NCT05102721 | |
| Cyclophosphamide GVAX PC Nivolumab Urelumab BMS-986253 |
Resectable Adenocarcinoma of the Pancreas | Phase II | NCT02451982 | |
| Nivolumab FOLFIRINOX |
Borderline Resectable PC | Early Phase I | NCT03970252 | |
| Cyclophosphamide Nivolumab GVAX Pancreas Vaccine Stereotactic Body Radiation (SBRT) |
Borderline Resectable PC | Phase II | NCT03161379 | |
| APX005M Nivolumab Nab-Paclitaxel GEM |
Metastatic Pancreatic Adenocarcinoma | Phase I and II | NCT03214250 | |
| Anetumab Ravtansine GEM Hydrochloride Ipilimumab Nivolumab |
Metastatic and recurrent Pancreatic Adenocarcinoma | Phase I and II | NCT03816358 | |
| Irreversible Electroporation (IRE) Nivolumab Toll-Like Receptor 9 |
Metastatic Pancreatic Adenocarcinoma | Phase I | NCT04612530 | |
| Nivolumab, ipilimumab Stereotactic body radiation therapy Low dose irradiation |
Stage IV PC | Phase I | NCT05088889 | |
| Pembrolizumab DEBIO1143 |
Adenocarcinoma of the Pancreas Adenocarcinoma of the Colon Adenocarcinoma of the Rectum |
Phase I | NCT03871959 | |
| Cyclophosphamide GVAX PC vaccine Pembrolizumab Stereotactic Body Radiation (SBRT) |
Locally Advanced PC | Phase II | NCT02648282 | |
| Stereotactic Body Radiation (SBRT) Nivolumab CCR2/CCR5 dual antagonist GVAX PC vaccine |
Locally Advanced PC | Phase I and II | NCT03767582 | |
| Anti-SEMA4D, Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab | Resectable Pancreatic and Colorectal Cancer | Phase I | NCT03373188 | |
| Pembrolizumab Olaparib |
Metastatic Pancreatic Adenocarcinoma | Phase II | NCT05093231 | |
| Gene Mediated Cytotoxic Immunotherapy (GMCI™) (aglatimagene besadenovec + valacyclovir) + chemoradiation+ surgery | Advanced Non-Metastatic Pancreatic Adenocarcinoma | Phase II | NCT02446093 | |
| Autologous Th-1 Dendritic Cell vaccine + chemotherapy | Pancreatic Adenocarcinoma | Phase I | NCT04157127 |